Volume 7, Issue 4, December 2019, Page: 125-128
Clinical Study of Quyuhuazhuo on Reducing Blood Hypercoagulability of Malignant Tumors
Aixia Sui, Department of Oncology, Hebei General Hospital, Shijiazhuang, China
Wenhua Xu, College of Nursing, Hebei University of Chinese Medicine, Shijiazhuang, China
Huayue Cong, Department of Oncology, Hebei General Hospital, Shijiazhuang, China; College of Postgraduate, North China University of Technology, Tangshan, China
Huiling Song, Department of Oncology, Hebei General Hospital, Shijiazhuang, China; College of Postgraduate, North China University of Technology, Tangshan, China
Yong Liu, Department of Oncology, Baoding First Central Hospital, Baoding, China
Haibo Jia, Department of Traditional Chinese Medicine, Hebei General Hospital, Shijiazhuang, China
Yongqing Shen, College of Nursing, Hebei University of Chinese Medicine, Shijiazhuang, China
Received: Aug. 28, 2019;       Accepted: Sep. 16, 2019;       Published: Sep. 27, 2019
DOI: 10.11648/j.crj.20190704.11      View  87      Downloads  25
Abstract
Objective: To investigate the clinical significance of Quyuhuazhuo on reducing blood stasis syndrome of malignant tumors (hypercoagulable state of blood). Methods: 60 malignant tumor patients with hypercoagulable state were randomly divided into treatment group and control group. In treatment group, 30 patients were treated with Quyuhuazhuo combined with chemotherapy. In control group, the other 30 patients received chemotherapy only. The clinical symptoms were observed. The changes of PLT (platelet), FIB (fibrinogen), PT (prothrombin time), APTT (activated partial thromboplastin time) and D-dimer were monitored dynamically before and after treatment. Result: The time of PT and APTT was prolonged significantly in treatment group compared with control group (P<0.05), and the value of PLT, FIB and D-dimer decreased significantly (P<0.05). Conclusion: The combined treatment of chemotherapy with Quyuhuazhuo can reduce the hypercoagulable state in malignant tumor patients.
Keywords
Quyuhuazhuo, Malignant TUmor, Blood Hypercoagulability, Blood Stasis
To cite this article
Aixia Sui, Wenhua Xu, Huayue Cong, Huiling Song, Yong Liu, Haibo Jia, Yongqing Shen, Clinical Study of Quyuhuazhuo on Reducing Blood Hypercoagulability of Malignant Tumors, Cancer Research Journal. Vol. 7, No. 4, 2019, pp. 125-128. doi: 10.11648/j.crj.20190704.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68 (6): 394-424.
[2]
Blane DN, Lewandowska M. Living with cancer and multimorbidity: the role of primary care. Curr Opin Support Palliat Care. 2019, 13 (3): 213-219.
[3]
Al-Samkari H, Connors JM. Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability. Am J Hematol. 2018, 93 (6): E156-E158.
[4]
Normile D. DRUG DISCOVERY. Nobel for antimalarial drug highlights East West divide. Science. 2015, 350 (6258): 265.
[5]
Araújo A. [Cancer and deep venous thrombosis: the purpose of the CATCH clinical trial]. Acta Med Port. 2013, 26 (2): 83-85.
[6]
Scărlătescu E, Lancé MD, White NJ, Aramă SS, Tomescu DR. Effects of malignancy on blood coagulation in septic intensive care patients. Blood Coagul Fibrinolysis. 2018, 29 (1): 92-96.
[7]
Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017, 117: 219–230.
[8]
Wang S, Long S, Wu W. Application of Traditional Chinese Medicines as Personalized Therapy in Human Cancers. Am J Chin Med. 2018, 46 (5): 953-970.
[9]
Al-Samkari, H; Connors, JM; Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability. Am J Hematol. 2018, 93 (6): E156-E158.
[10]
Hsu JY, Liu AB. Anticoagulants for cancer-associated ischemic stroke. Ci Ji Yi Xue Za Zhi. 2019, 31 (3): 144-148.
[11]
Ling CQ, Yue XQ, Ling C. Three advantages of using traditional Chinese medicine to prevent and treat tumor. J Integr Med. 2014, 12 (4): 331-335.
[12]
Xi SY, Minuk GY. Role of traditional Chinese medicine in the management of patients with hepatocellular carcinoma. World J Hepatol. 2018, 10 (11): 799-806.
[13]
Kang XJ, Wang HY, Peng HG, Chen BF, Zhang WY, Wu AH, Xu Q, Huang YZ. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Acta Pharmacol Sin. 2017, 38 (6): 885-896.
[14]
Zang W, Bian H, Huang X, Yin G, Zhang C, Han LI, Hao P, Ding S, Sun YU, Yang Z, Hoffman RM, Tang D. Traditional Chinese Medicine (TCM) Astragalus Membranaceus and Curcuma Wenyujin Promote Vascular Normalization in Tumor-derived Endothelial Cells of Human Hepatocellular Carcinoma. Anticancer Res. 2019, 39 (6): 2739-2747.
[15]
Campello E, Ilich A, Simioni P, Key NS. The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. Br J Cancer. 2019 Jul 22. doi: 10.1038/s41416-019-0510-x. [Epub ahead of print]
Browse journals by subject